Mathematical modelling long-term effects of replacing Prevnar7 with Prevnar13 on invasive pneumococcal diseases in England and Wales.
England and Wales recently replaced the 7-valent pneumococcal conjugate vaccine (PCV7) with its 13-valent equivalent (PCV13), partly based on projections from mathematical models of the long-term impact of such a switch compared to ceasing pneumococcal conjugate vaccination altogether.A compartmenta...
Main Authors: | Yoon Hong Choi, Mark Jit, Stefan Flasche, Nigel Gay, Elizabeth Miller |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2012-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3396640?pdf=render |
Similar Items
-
From “Glivec®” to “Prevnar 13®”: How strong is the Indian drug patenting system?
by: Gerard Marshall Raj
Published: (2018-01-01) -
Sequential administration of Prevnar 13™ and PNEUMOVAX™ 23 in healthy participants 50 years of age and older
by: Ulrike K. Buchwald, et al.
Published: (2021-08-01) -
Rapid kinetics of serum IgA after vaccination with Prevnar®13 followed by Pneumovax®23
by: Rebecca R. Crowther, et al.
Published: (2017-02-01) -
Poor Long-Term Efficacy of Prevnar-13 in Sickle Cell Disease Mice Is Associated with an Inability to Sustain Pneumococcal-Specific Antibody Titers.
by: Steven M Szczepanek, et al.
Published: (2016-01-01) -
7-Valent pneumococcal conjugate vaccination in England and Wales: is it still beneficial despite high levels of serotype replacement?
by: Yoon Hong Choi, et al.
Published: (2011-01-01)